The pharma sector in India continues to show resilience and positive momentum despite global economic uncertainties, as the rating agency, India Ratings and Research (Ind-Ra) in its latest report has showed that the Indian pharmaceutical market (IPM) sustained double-digit growth in the month of April 2026, rising by 10.1% year on year (Y-o-Y) in the reported month.

According to India Ratings and Research, the growth in Indian pharmaceutical market during April was on account of a recovery in volumes, steady price increases, and new product launches. The rating agency further noted that the performance marks a continuation of the growth pick-up observed since December 2025.

Besides, the report stated that April 2026 marked growth in the pharma sector, as prices increased by 5.6%, new products launches witnessed a growth of 3.6%, and volumes surged by 1%. It said the anti-diabetic segment reported strong growth of 16.2% month-on-month during April 2026, led by new product growth of 12.3% due to the launch of GLP-1 agonist products during March 2026.